Stryker (NYSE:SYK) Sets New 12-Month Low – Should You Sell?

Stryker Corporation (NYSE:SYK)’s stock price reached a new 52-week low on Wednesday . The company traded as low as $275.10 and last traded at $276.1560, with a volume of 6316453 shares traded. The stock had previously closed at $303.13.

Wall Street Analyst Weigh In

SYK has been the subject of a number of research analyst reports. Citizens Jmp dropped their price objective on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a report on Monday, August 3rd. Evercore set a $350.00 price target on Stryker in a research report on Monday, July 6th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Citigroup reiterated a “buy” rating on shares of Stryker in a report on Thursday, August 13th. Finally, Royal Bank Of Canada dropped their target price on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Stock Down 8.9%

The firm has a 50-day simple moving average of $327.52 and a 200 day simple moving average of $328.30. The company has a market capitalization of $105.93 billion, a PE ratio of 28.62, a price-to-earnings-growth ratio of 1.90 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts predict that Stryker Corporation will post 15.03 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.3%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Insider Transactions at Stryker

In other news, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda Stryker sold 300,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the sale, the director directly owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 351,267 shares of company stock valued at $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Stryker

Institutional investors and hedge funds have recently made changes to their positions in the business. Brighton Jones LLC grew its stake in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares in the last quarter. Schnieders Capital Management LLC. acquired a new position in Stryker during the 2nd quarter valued at approximately $205,000. Marshall Wace LLP grew its stake in Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after buying an additional 77,831 shares during the last quarter. Nebula Research & Development LLC bought a new position in Stryker during the 2nd quarter worth $219,000. Finally, HUB Investment Partners LLC acquired a new stake in Stryker in the second quarter worth $253,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

About Stryker

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.